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Background: The ADAMs (A Disintegrin and Metalloproteinases) are a family of multi-domain, zinc-dependent
metalloproteinase enzymes. ADAM 12 has been previously associated with the onset and progression of breast
cancer, and elevated levels of ADAM 12 have been previously found in the urine of breast cancer patients. Aims
of the current study are: 1) establish the viability of urinary ADAM 12 as a diagnostic marker for breast cancer, and
2) explore the effects of surgical tumor removal on the levels of urinary ADAM 12.
Methods: A total of 96 patients have been recruited for this study, including 50 patients diagnosed with cancer,
and 46 age-matched controls. Commercially available ELISA kits for ADAM 12 were used to quantify the presence
and concentration of this enzyme in the urine from cancer patients with ductal carcinoma in situ (DCIS) and
invasive breast cancer (IBC) both prior to any treatment and approximately two weeks following surgery, as well
as from controls.
Results: We find no statistically significant differences between the concentrations of ADAM 12 in the urine of
breast cancer patients prior to treatment and that of their age-matched controls; however the concentration
of ADAM 12, both alone and as a function of urine total protein, are significantly elevated following surgery
(p < 0.0001). Patients who underwent a mastectomy have significantly higher urinary ADAM 12 concentrations
than those who underwent a lumpectomy (significant at p = 0.0271).
Conclusions: These findings suggest that urinary ADAM 12 may not correlate directly with the status and stage of
breast cancer as previously thought; rather these increases may be a result of tissue injury and inflammation from
biopsy and surgical resection. Results of this study may suggest a need for biomarkers to be evaluated carefully in
the context of tissue damage.
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Breast cancer is currently the second leading cause of
cancer deaths among women in the United States
(second only to lung cancer), and it is now estimated
that in the U.S. one in eight women will be diagnosed
with breast cancer during her lifetime [1]. However, if
breast cancer is detected during its earlier stages, the
5-year survival rate may be as high as 93% (at stage* Correspondence: Neville.Alberto@sanfordhealth.org
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article, unless otherwise stated.0; this reflects death from all causes); when detected
at stage IIIB and later, 5-year survival rate drops
below 50% [2], making early detection of breast cancer
essential for favorable prognosis. Tumor markers
currently in use in the evaluation of breast cancer
include (but are not limited to) cancer antigen 15-3
[3,4] and 125 [5] (CA15-3, CA 125), carcinoembryonic
antigen [3,4] (CEA), and prolactin [6]; however these show
little potential for early detection [7]. Recent studies have
begun exploring the potential of urinary biomarkers forCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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the ADAM proteases [10], particularly ADAM 12 [11-13].
The ADAMs (A Disintegrin and Metalloproteinases)
are a family of multi-domain, zinc-dependent metallo-
proteinase enzymes. There are currently 40 known genes
for ADAMs, 21 of which are known to function in
humans [14]. ADAMs are usually membrane bound
(although some members of the ADAM family have
secreted forms, including ADAM-9 [15], -10 [16], -12
[17] and -28 [18-20]), and their physiological roles
include extracellular matrix restructuring [21-23], cell
adhesion [24-26], and cell-surface protein processing
[27-29]. ADAM 12, which is transcribed as both a
membrane bound (ADAM 12-L) and a secreted form
(ADAM 12-S), has roles in cell adhesion and matrix
restructuring during cell differentiation [24-26,30],
and also has regulatory functions [31] in healthy
tissues. ADAM 12 has also been associated with
development and progression of a number of disease
states, including arthritis [32], cardiac hypertrophy
[33], liver fibrogenesis [34], and various cancers,
including bladder [35], lung [36], brain [37] and breast
[11]. It has also been suggested that the ADAM 12
produced by the tumor cells drives the progression of
breast tumors [38]. Further, a study conducted in
2012 correlates gene expression of both ADAM 12 and
ADAM 17 with clinical and pathological characteristics of
breast cancer [39].
One study in 2004 indicated a strong correlation
between excretion of urinary ADAM 12 and breast
cancer status and stage [11]. This report concluded that
patients with ductal carcinoma in situ (DCIS), invasive
breast cancer (IBC), and metastatic breast cancer had
significantly higher levels of ADAM 12 present in their
urine than controls (i.e. patients with “no discernible
disease”) [11]. The report further concluded that only
15% of the control subjects had detectable levels of
ADAM 12 present in their urine, while 82%, 86%, and
85% of patients with DCIS, IBC and metastatic disease,
respectively, were positive for the presence of ADAM 12
[11]. These results strongly suggest that a urine test for
ADAM 12 would prove especially useful for the diagnosis
of breast cancers, stage DCIS and later.
The aims of the current study are twofold: 1) establish
the viability of urinary ADAM 12 as a diagnostic marker
for breast cancer, and 2) explore the effects of surgical
tumor removal on the levels of urinary ADAM 12. We
hypothesize that, as previous reports suggest that breast
tumor progression is responsible for the increased
ADAM 12, the urinary ADAM 12 concentrations will be
significantly higher in cancer patients than controls, and
that urinary ADAM 12 levels will decrease following
tumor removal. Our primary objective is to establish a
simple, practical test for the early detection of breastcancer. As such, we have chosen to utilize commercially
available ELISA kits for urinary ADAM 12 measurements:
we reason that they are a well accepted technology, which
will provide reliable, reproducible results in a clinic setting.
Methods
Ethics review and approval
This study was conducted in compliance with the
Helsinki Declaration. The protocol, informed consent
form, and laboratory manuals for this study were reviewed
and approved by the Sanford Health Institutional Review
Board in compliance with its Federalwide Assurance
(#00016819). All patients’ participation was voluntary, and
all enrolled participants were given the right to refuse or
exit the study at any time. Participants’ were given a
unique study number; and therefore their specimens
and related medical information were de-identified.
Participant’s study related medical record information
was protected in accordance with HIPAA regulation.
Materials
Coomassie Blue (Bradford) Assay Kit was obtained
from Thermo Scientific (Rockford, IL), and 96-well
polystyrene plates for this assay were obtained from
Greiner Bio-One (Monroe, NC). ADAM 12 enzyme
linked immunosorbent assay (ELISA) kits obtained
from R&D Systems (Minneapolis, MN). All supplies
used without any further modifications.
Patient recruitment
Study participants were screened during their visit either
to the Sanford Breast Clinic and/or breast surgeon
consultation visit by their treatment provider. If they
wished to participate in the study, the clinical research
coordinator met with them to discuss and/or complete
the Informed Consent Form (ICF) document and
process. After consent was obtained, the coordinator
collected the pre-surgery or control urine sample, and
informed those participants with breast cancer of the
need to leave a second sample at a follow-up visit after
their surgery. Control patients were matched for age and
co-morbidities. They were selected from Sanford
Medical Center Breast Clinic or other clinics. If they
had benign and non interventional breast findings they
were approached at their clinic visit about participation in
the study and appropriately consented. Controls were
consented using the same ICF document and process as
breast cancer subjects.
Inclusion criteria:
 Females age 21 years of age or older
 Recent diagnosis of breast cancer
 No previous diagnosis of cancer, excepting
non-melanoma skin cancer.
Table 1 Urinary ADAM 12 of cancer patient group vs. control group
Cancer group: pre-surgery Cancer group: post-surgery Control group
(n = 50) (n = 49) (n = 46)
Age Mean: 60.9 ± 13.0 Mean: 60.9 ± 13.0 Mean: 60.1 ± 12.4
Median: 60 Median: 60 Median: 60
[ADAM 12] (ng/mL) Mean: 3.36 ± 3.04 Mean: 16.3 ± 15.6 Mean: 3.52 ± 3.17
Median: 2.48 Median: 10.3 Median: 2.77
Total protein (μg/mL) Mean: 60.7 ± 53.6 Mean: 59.7 ± 32.9 Mean: 78.6 ± 65.6
Median: 42.0 Median: 59.0 Median: 58.7
ADAM 12 as % of total protein Mean: 0.008 ± 0.01 Mean: 0.03 ± 0.03 Mean: 0.006 ± 0.006
Median: 0.005 Median: 0.017 Median: 0.004
Cancer group consists of DCIS (n = 15) and IBC (n = 35) diagnoses.
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 Advanced stage breast cancer disease (i.e., stage
4 cancer with multiple metastasis)
Age-matched controls were females with no positive
history of breast cancer or other previous diagnosed
cancers, excluding non-melanoma skin cancer. All
patients were recruited for study from the Sanford
Medical Breast Clinics, and were consented in accordance
with institutional regulatory board guidelines. All breast
cancer patients had surgery as their initial treatment. The
surgeries involved either a lumpectomy or a mastectomy
for local control of their cancer; and in most cases axillary
sentinel lymph node dissection was included. When
indicated, a level I and II axillary lymph node dissection
was done as part of the same procedure based on frozen
section evaluation on the sentinel lymph nodes. The deci-
sion of surgery options was made after multidisciplinary
treatment planning, consultation with the patients, and
followed National Cancer Cooperative Network (NCCN)
guidelines.
Urine collection and processing
Following consent, patients and controls were brought
to a private area and asked to leave a urine sample.
Immediately following collection, the urine was well
mixed, and ten milliliters (10 mL) was aliquoted into a
sterile, 10 mL screw cap test tube, and labeled with
the patients de-identified information only; available
information includes only patient age, stage of cancer,
tumor size and co-morbidities. These samples were
immediately placed upright in a -80°C freezer for storage.
Recruited breast cancer patients provided two samplesof urine, one just following diagnosis, and a second
approximately two weeks following surgery to remove
the tumor mass (all patients recruited for this study
were scheduled for surgery). Controls have provided
one sample only. Upon collection of 20 samples, tubes
were transported to North Dakota State University on dry
ice for testing.
Prior to testing, samples were thawed on ice and
centrifuged at 200 rcf for 15 minutes to remove any
particulates. The resulting supernatant was diluted 1:5 in
one of two buffers: for the Bradford assay, 50 mM Tris
at pH 8 was used, and for ELISA the calibrator diluent
provided with the kit was used, as per the manufacturer’s
suggestion. Preliminary data demonstrated the necessity
of dilution such that the patient samples would fit within
the standard curve of both the Bradford assay and the
ADAM 12 ELISA.
Bradford assay
Manufacturer’s instructions for the “micro microplate
procedure” obtained with the kit were followed regarding
volumes of samples, standards, and assay reagent. Bovine
serum albumin was provided with the kit, and was
used to produce the standard curve. The 2 mg/mL
albumin standard was diluted in 50 mM Tris buffer
(pH 8) to produce a standard curve ranging from
zero μg/mL to 100 μg/mL. Twenty patient and/or
control urine samples diluted 1:5 (see Section on
Urine collection and processing) were loaded into four
wells each of a 96-well standard clear bottom polystyrene
plate, 150 μL per well. Standard samples were also loaded,
two wells each sample, 150 μL per well. Bradford
assay reagent provided was loaded into each well,
150 μL per well, and the plate was mixed on a shaker
for 10 seconds, followed by incubation at room
temperature for 10 minutes. Reading of plate absorbance,
production of the standard curve and analysis of the
samples was performed according to manufacturer’s
instructions.
Figure 1 Boxplots showing urinary ADAM 12 levels in patient
groups (pre- and post-surgery) vs. control group; concentration
of ADAM 12 denoted in ng/mL (a), total protein concentration
(b), and ADAM 12 as a% of total protein (c) are shown for each
respective group. Circles above and below the box denote 99%
and 1%, respectively; vertical bars denote 10-90%; the box denotes
25-75%; the small square denotes the mean; and the horizontal bar
denotes the median. ** p < 0.0001.
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Twenty patient and/or control urine samples diluted
1:5 (see section on urine collection and processing)
were loaded into four wells each of the provided 96-well
plate of a commercially available ELISA kit. Standard
samples were also loaded, two wells each. Manufacturer’s
instructions were followed for production of standard
curve and analysis of samples. The antibodies provided
with this kit consist of monoclonal antibodies specific for
ADAM 12.
Statistical analysis
Groups were compared using nonparametric Mann-
Whitney test (α = 0.05). Analysis was performed using
Minitab (v. 16.1.1).
Results
A total of 50 patients with the diagnosis of breast cancer
and 46 age matched control patents were recruited
into the study. Based on the data collected, no significant
differences exist between the urinary ADAM 12 concen-
trations of the control patients and the cancer patients
prior to their surgery. The urinary concentration of
ADAM 12 increased significantly following patient
surgery (p < 0.0001), both in ng/mL and as a function
of total urine protein. Results are summarized in Table 1
and Figure 1 below.
The cancer patients recruited for this study consist of
15 women with a diagnosis of DCIS, and 35 women with
a diagnosis of IBC (30% and 70% of the total group,
respectively). If we consider these as separate groups
and compare these groups individually to the control
group the results do not change, nor do the DCIS and
IBC patients differ significantly from each other pre-surgery
(see Figure 2). The ADAM 12 concentration ranges and
median changes in concentration from pre- to post-surgery
are also consistent between the DCIS and IBC groups
(see Table 2). Significant elevation of urinary ADAM
12 does take place after patients have undergone surgery
(overall p-value < 0.0001).
Results further suggest a link between the extent of
patient surgery and urinary ADAM 12 elevation. Of the
cancer patients recruited for this study, 38 of these
underwent lumpectomies, and 11 underwent mastectomies
(77.6% and 22.4% of the total group, respectively; one of
Figure 2 Boxplots showing urinary ADAM 12 concentration in
ng/mL pre- and post- surgery for DCIS patients only (a), IBC
patients only (b), and both DCIS and IBC patients pre-surgery
(c) with comparison to the control group. Circles above and below
the box denote 99% and 1%, respectively; vertical bars denote
10-90%; the box denotes 25-75%; the small square box denotes
the mean; and the horizontal bar denotes the median. * p = 0.0003,
# p = 0.0128, ** p < 0.0001.
Table 2 Ranges and median change of ADAM 12
concentration for controls and cancer patients (by stage)
Stage Pre-surgery Post-surgery Median change
Control 0—11.01 ng/mL NA NA
DCIS 0.6—15.8 ng/mL 1.0—53.8 ng/mL 5.4
IBC 0.1—11.1 ng/mL 1.1—53.8 ng/mL 7.5
Table 3 Ranges and median change of ADAM 12
concentration for lumpectomy patients vs. mastectomy
patients (compared to controls)
Surgery Pre-surgery Post-surgery Median change
Control 0—11.0 ng/mL NA NA
Lumpectomy 0.1—15.8 ng/mL 1.0—53.8 ng/mL 4.8
Mastectomy 0.4—7.6 ng/mL 6.4—53.8 ng/mL 14.7
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sample). The concentration of ADAM 12 in the urine
of mastectomy patients was significantly higher than
that of lumpectomy patients post-surgery (p = 0.0075);the median increase in ADAM 12 concentration for
mastectomy patients was 14.7 ng/mL, versus 4.8 ng/mL
for lumpectomy patients. The median percent increase in
urinary ADAM 12 concentration following surgery
was 313.6% for lumpectomy patients, and 764.5% for
mastectomy patients. When considered as a percentage of
total protein, the percent urinary ADAM 12 following a
mastectomy versus that following a lumpectomy was
significant at p = 0.0013. There were no statistically
significant differences between the total urine protein
concentrations of these groups. These results are summa-
rized in Table 3 and Figure 3. There were no significant
differences between the urinary ADAM 12 concentrations
of lumpectomy and mastectomy patients prior to their
surgeries (data not shown).
Discussion
Interestingly, the current results appear to contradict those
published in 2004 [11]; while these authors have concluded
that patients with DCIS and IBC had significantly higher
levels of ADAM 12 in their urine, our data shows no
significant difference between the cancer and control
groups. It should here be noted that this group has
evaluated the patient concentration of urinary ADAM
12 by western blot, and they have used polyclonal
antibodies directed against the cysteine rich domain
of ADAM 12 in their analysis [11,35]. We believe that this
difference in technique alone should not have resulted in
these significant variations in results.
In addition, there is also an apparent conflict between
the current results and those published in 2012 [39].
These authors have observed an increase in the genetic
expression of both ADAM 12 and ADAM 17 in malignant
breast tissue. However, it should be noted that their
results also suggest that the expression levels of ADAM
12-L (the membrane bound form) are considerably more
elevated than those of ADAM 12-S (the secreted form)
Figure 3 Boxplots showing urinary ADAM 12 levels in patients
who underwent lumpectomies or mastectomies vs. control group;
concentration of ADAM 12 denoted in ng/mL (a), total protein
concentration (b), and ADAM 12 as a% of total protein (c) are
shown for each respective group. Circles above and below the box
denote 99% and 1%, respectively; vertical bars denote 10-90%; the box
denotes 25-75%; the small square denotes the mean; and the horizontal
bar denotes the median. * p = 0.0075, ** p < 0.0001, + p = 0.0013.
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not distinguish between ADAM 12-L and ADAM 12-S.
This suggests that the elevation of ADAM 12 protein seen
during this study was likely primarily elevation of ADAM
12-L, and as this form is membrane bound, it is far less
likely to end up in the patient’s urine.
The current results raise a number of interesting
questions. The observed elevation in ADAM 12 following
surgery is not surprising: many matrix metalloproteinase
enzymes are upregulated during wound healing [40], and
evidence suggests that ADAM 12 is involved in tissue
remodeling [41], making it likely to undergo upregulation
following surgical or other trauma to the tissues. We also
note a priori that many patients recruited for this study
have co-morbidities which may affect levels of ADAM 12
(e.g. osteoarthritis [32], allergic rhinitis [42], and asthma
[43]; however these co-morbidities are well balanced
between the cancer group and the control group, and
based on our analysis they have had no significant effect
on the concentrations of urinary ADAM 12. The data also
shows that some cancer and control patients having levels
of ADAM 12 above the median did not have obvious
co-morbidities. It remains to be determined under
what circumstances members of a certain group could
have significantly elevated levels of urinary ADAM 12
compared to members of another group, assuming
these groups are age-matched. Based on our observations,
these circumstances could easily occur if the group having
elevated urinary ADAM 12 had undergone surgery within
four weeks of having been tested. Further, as those
patients with more advanced stages of cancer would be
likely to have had more extensive surgery; it would follow
that those patients with higher stage breast cancers would
appear to have higher urinary ADAM 12 concentrations.
Other tissue trauma could also play a role, such as
biopsies. Further, if existing co-morbidities had not been
well balanced between the control and test groups, it is
likely these could have played a role in the elevation of
urinary ADAM 12 levels in one group over another.
As a final consideration we note that in 2011, the same
group (which concluded in 2004 that DCIS patients
have significantly elevated urinary ADAM 12 vs. controls)
has conducted another study (utilizing fluorescent
metalloproteinase substrates) to simultaneously detect a
number of matrix metalloproteinases (MMP-1, -2, -3, -8, -9,
and -13) and ADAMs (ADAM-8, -9, -10, -12, and -17)
in the urine of cancer patients and age-matched controls.
This study concluded that no statistical difference exists
between DCIS patients and age-matched controls when
this polymer-based method is used [12]. Due to these
contradictory results, further studies are necessary in
order either to accept or to reject the measurement of
urinary ADAM 12 as a viable method for the diagnosis of
breast cancer.
Nyren-Erickson et al. Journal of Negative Results in BioMedicine 2014, 13:5 Page 7 of 8
http://www.jnrbm.com/content/13/1/5Conclusions
We find no significant difference between urinary ADAM
12 concentrations in patients diagnosed with DCIS or IBC
and their age-matched controls prior to any surgery or
other therapeutic treatment. Further, we find no significant
differences in urinary ADAM 12 concentrations between
DCIS patients and IBC patients either prior to or following
surgical treatment. These results are in contrast to those
published by another group in 2004 [11].
Following surgical treatment, the concentrations of urin-
ary ADAM 12 are elevated significantly over age-matched
controls, and the degree of this increase depends upon the
extent of the surgery.
These conclusions suggest that an increase in the
concentration of urinary ADAM 12 may not correlate
directly with the status and stage of breast cancer as
previously thought; rather these increases may be a
result of tissue injury and inflammation from biopsy and
surgical resection. Further studies are necessary to
accept or reject the measurement of urinary ADAM 12
as a viable method for the diagnosis of breast cancer.
The above results may suggest a need for biomarkers
to be evaluated carefully in the context of tissue damage.
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